http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Fri, 07 Aug 2026 04:37:37 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Intl+Ratings/Genmab+AS+%28GEN%3ADC%29+%28GMAB%29+PT+Raised+to+DKK2%2C700+at+UBS/26886465.html UBS analyst Xian Deng raised the price target on Genmab A/S (GEN:DC) (NASDAQ: GMAB) to DKK2,700.00 (from DKK2,600.00) while maintaining a Buy rating. http://www.streetinsider.com/Intl+Ratings/Genmab+AS+%28GEN%3ADC%29+%28GMAB%29+PT+Raised+to+DKK2%2C700+at+UBS/26886465.html Fri, 07 Aug 2026 04:37:37 -0400 GMAB http://www.streetinsider.com/Intl+Ratings/Genmab+AS+%28GEN%3ADC%29+%28GMAB%29+PT+Raised+to+DKK2%2C700+at+UBS/26886465.html UBS analyst Xian Deng raised the price target on Genmab A/S (GEN:DC) (NASDAQ: GMAB) to DKK2,700.00 (from DKK2,600.00) while maintaining a Buy rating. http://www.streetinsider.com/Intl+Ratings/Genmab+AS+%28GEN%3ADC%29+%28GMAB%29+PT+Raised+to+DKK2%2C700+at+UBS/26886465.html Fri, 07 Aug 2026 04:37:37 -0400 GMAB http://www.streetinsider.com/Analyst+PT+Change/Genmab+AS+%28GEN%3ADC%29+%28GMAB%29+PT+Raised+to+DKK2%2C700+at+UBS/26886465.html UBS analyst Xian Deng raised the price target on Genmab A/S (GEN:DC) (NASDAQ: GMAB) to DKK2,700.00 (from DKK2,600.00) while maintaining a Buy rating. http://www.streetinsider.com/Analyst+PT+Change/Genmab+AS+%28GEN%3ADC%29+%28GMAB%29+PT+Raised+to+DKK2%2C700+at+UBS/26886465.html Fri, 07 Aug 2026 04:37:37 -0400 GMAB http://www.streetinsider.com/Analyst+PT+Change/Genmab+AS+%28GEN%3ADC%29+%28GMAB%29+PT+Raised+to+DKK2%2C700+at+UBS/26886465.html UBS analyst Xian Deng raised the price target on Genmab A/S (GEN:DC) (NASDAQ: GMAB) to DKK2,700.00 (from DKK2,600.00) while maintaining a Buy rating. http://www.streetinsider.com/Analyst+PT+Change/Genmab+AS+%28GEN%3ADC%29+%28GMAB%29+PT+Raised+to+DKK2%2C700+at+UBS/26886465.html Fri, 07 Aug 2026 04:37:37 -0400 GMAB http://www.streetinsider.com/Investing/Genmab+stock+falls+despite+H1+revenue+rise/26882299.html <p>Investing.com -- Genmab A/S reported first-half 2026 revenue of $2.05 billion, up 25% YoY from $1.64 billion in the same period last year, though shares fell 2.6% following the announcement on Thursday.</p> <p>The Danish biotechnology company&amp;#39;s revenue growth was primarily driven by higher DARZALEX and Kesimpta royalties and increased EPKINLY net product sales. Royalty revenue reached $1.708 billion, up 24% from $1.378 billion in the first half of 2025. Global net sales of EPKINLY/TEPKINLY surged 48% to $312 million from $211 million YoY.</p> <p>Adjusted operating expenses rose 28% to $1.27 billion from $993 million, driven by investments in the product pipeline, including advancement http://www.streetinsider.com/Investing/Genmab+stock+falls+despite+H1+revenue+rise/26882299.html Thu, 06 Aug 2026 13:20:42 -0400 GMAB http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++GENMAB+AS++++++++++++++++For%3A+Jun+30/26881630.html si-local-file:///var/storage/secattach/20260806/26881630.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++GENMAB+AS++++++++++++++++For%3A+Jun+30/26881630.html Thu, 06 Aug 2026 11:09:00 -0400 GMAB GMAB O.00290225 http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++GENMAB+AS++++++++++++++++For%3A+Jun+30/26881630.html si-local-file:///var/storage/secattach/20260806/26881630.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++GENMAB+AS++++++++++++++++For%3A+Jun+30/26881630.html Thu, 06 Aug 2026 11:09:00 -0400 GMAB GMAB O.00290225 http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++GENMAB+AS++++++++++++++++For%3A+Jun+30/26881630.html si-local-file:///var/storage/secattach/20260806/26881630.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++GENMAB+AS++++++++++++++++For%3A+Jun+30/26881630.html Thu, 06 Aug 2026 11:09:00 -0400 GMAB GMAB O.00290225 http://www.streetinsider.com/Corporate+News/Genmab+revenue+rises+25%25+in+first+half+of+2026%2C+guidance+raised/26881593.html <p>Genmab A/S reported revenue of $2,051 million for the first six months of 2026, a 25% increase from $1,640 million in the same period of 2025, according to the company's interim report released August 6.</p><p>The revenue growth was driven primarily by higher royalties from DARZALEX and Kesimpta, as well as increased net product sales of EPKINLY. Royalty revenue rose 24% to $1,708 million. Net sales of DARZALEX by Johnson & Johnson reached $8,171 million in the first half of 2026, up 21% from $6,776 million a year earlier. Global net sales of EPKINLY/TEPKINLY grew 48% to $312 million.</p><p>Operating profit was http://www.streetinsider.com/Corporate+News/Genmab+revenue+rises+25%25+in+first+half+of+2026%2C+guidance+raised/26881593.html Thu, 06 Aug 2026 11:02:57 -0400 GMAB http://www.streetinsider.com/Press+Releases/Genmab+Announces+Financial+Results+for+the+First+Half+of+2026/26881588.html <p><b>August 6, 2026 Copenhagen, Denmark; </b><br/><b>Interim Report for the Six Months Ended June 30, 2026</b></p> <p><b>Highlights</b></p> <ul type="disc"><li><b>Genmab announced positive Phase 3 results for epcoritamab plus lenalidomide in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL), demonstrating statistically significant improvement in progression-free survival</b></li><li><b>Genmab revenue </b><b>increased</b> <b>25%</b><b> compared to the first six months of </b><b>2025</b><b>, to </b><b>$2,051 million</b></li><li><b>Genmab 2026 financial guidance updated</b><br/><br/></li></ul> <p>“The second quarter of 2026 delivered clinical progress for our late-stage portfolio. Epcoritamab continued to demonstrate its potential as a core therapy across the spectrum of B-cell malignancies, with strong data across multiple treatment settings and http://www.streetinsider.com/Press+Releases/Genmab+Announces+Financial+Results+for+the+First+Half+of+2026/26881588.html Thu, 06 Aug 2026 11:01:00 -0400 0MGB GMAB GMAB O.00290225 http://www.streetinsider.com/Press+Releases/Genmab+Announces+Financial+Results+for+the+First+Half+of+2026/26881588.html <p><b>August 6, 2026 Copenhagen, Denmark; </b><br/><b>Interim Report for the Six Months Ended June 30, 2026</b></p> <p><b>Highlights</b></p> <ul type="disc"><li><b>Genmab announced positive Phase 3 results for epcoritamab plus lenalidomide in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL), demonstrating statistically significant improvement in progression-free survival</b></li><li><b>Genmab revenue </b><b>increased</b> <b>25%</b><b> compared to the first six months of </b><b>2025</b><b>, to </b><b>$2,051 million</b></li><li><b>Genmab 2026 financial guidance updated</b><br/><br/></li></ul> <p>“The second quarter of 2026 delivered clinical progress for our late-stage portfolio. Epcoritamab continued to demonstrate its potential as a core therapy across the spectrum of B-cell malignancies, with strong data across multiple treatment settings and http://www.streetinsider.com/Press+Releases/Genmab+Announces+Financial+Results+for+the+First+Half+of+2026/26881588.html Thu, 06 Aug 2026 11:01:00 -0400 0MGB GMAB GMAB O.00290225 http://www.streetinsider.com/Press+Releases/Genmab+Announces+Financial+Results+for+the+First+Half+of+2026/26881588.html <p><b>August 6, 2026 Copenhagen, Denmark; </b><br/><b>Interim Report for the Six Months Ended June 30, 2026</b></p> <p><b>Highlights</b></p> <ul type="disc"><li><b>Genmab announced positive Phase 3 results for epcoritamab plus lenalidomide in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL), demonstrating statistically significant improvement in progression-free survival</b></li><li><b>Genmab revenue </b><b>increased</b> <b>25%</b><b> compared to the first six months of </b><b>2025</b><b>, to </b><b>$2,051 million</b></li><li><b>Genmab 2026 financial guidance updated</b><br/><br/></li></ul> <p>“The second quarter of 2026 delivered clinical progress for our late-stage portfolio. Epcoritamab continued to demonstrate its potential as a core therapy across the spectrum of B-cell malignancies, with strong data across multiple treatment settings and http://www.streetinsider.com/Press+Releases/Genmab+Announces+Financial+Results+for+the+First+Half+of+2026/26881588.html Thu, 06 Aug 2026 11:01:00 -0400 0MGB GMAB GMAB O.00290225 http://www.streetinsider.com/Press+Releases/Genmab+Announces+Financial+Results+for+the+First+Half+of+2026/26881588.html <p><b>August 6, 2026 Copenhagen, Denmark; </b><br/><b>Interim Report for the Six Months Ended June 30, 2026</b></p> <p><b>Highlights</b></p> <ul type="disc"><li><b>Genmab announced positive Phase 3 results for epcoritamab plus lenalidomide in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL), demonstrating statistically significant improvement in progression-free survival</b></li><li><b>Genmab revenue </b><b>increased</b> <b>25%</b><b> compared to the first six months of </b><b>2025</b><b>, to </b><b>$2,051 million</b></li><li><b>Genmab 2026 financial guidance updated</b><br/><br/></li></ul> <p>“The second quarter of 2026 delivered clinical progress for our late-stage portfolio. Epcoritamab continued to demonstrate its potential as a core therapy across the spectrum of B-cell malignancies, with strong data across multiple treatment settings and http://www.streetinsider.com/Press+Releases/Genmab+Announces+Financial+Results+for+the+First+Half+of+2026/26881588.html Thu, 06 Aug 2026 11:01:00 -0400 0MGB GMAB GMAB O.00290225 http://www.streetinsider.com/Globe+Newswire/Genmab+Announces+Financial+Results+for+the+First+Half+of+2026/26881588.html <p><b>August 6, 2026 Copenhagen, Denmark; </b><br/><b>Interim Report for the Six Months Ended June 30, 2026</b></p> <p><b>Highlights</b></p> <ul type="disc"><li><b>Genmab announced positive Phase 3 results for epcoritamab plus lenalidomide in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL), demonstrating statistically significant improvement in progression-free survival</b></li><li><b>Genmab revenue </b><b>increased</b> <b>25%</b><b> compared to the first six months of </b><b>2025</b><b>, to </b><b>$2,051 million</b></li><li><b>Genmab 2026 financial guidance updated</b><br/><br/></li></ul> <p>“The second quarter of 2026 delivered clinical progress for our late-stage portfolio. Epcoritamab continued to demonstrate its potential as a core therapy across the spectrum of B-cell malignancies, with strong data across multiple treatment settings and http://www.streetinsider.com/Globe+Newswire/Genmab+Announces+Financial+Results+for+the+First+Half+of+2026/26881588.html Thu, 06 Aug 2026 11:01:00 -0400 0MGB GMAB GMAB O.00290225 http://www.streetinsider.com/Globe+Newswire/Genmab+Announces+Financial+Results+for+the+First+Half+of+2026/26881588.html <p><b>August 6, 2026 Copenhagen, Denmark; </b><br/><b>Interim Report for the Six Months Ended June 30, 2026</b></p> <p><b>Highlights</b></p> <ul type="disc"><li><b>Genmab announced positive Phase 3 results for epcoritamab plus lenalidomide in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL), demonstrating statistically significant improvement in progression-free survival</b></li><li><b>Genmab revenue </b><b>increased</b> <b>25%</b><b> compared to the first six months of </b><b>2025</b><b>, to </b><b>$2,051 million</b></li><li><b>Genmab 2026 financial guidance updated</b><br/><br/></li></ul> <p>“The second quarter of 2026 delivered clinical progress for our late-stage portfolio. Epcoritamab continued to demonstrate its potential as a core therapy across the spectrum of B-cell malignancies, with strong data across multiple treatment settings and http://www.streetinsider.com/Globe+Newswire/Genmab+Announces+Financial+Results+for+the+First+Half+of+2026/26881588.html Thu, 06 Aug 2026 11:01:00 -0400 0MGB GMAB GMAB O.00290225 http://www.streetinsider.com/Globe+Newswire/Genmab+Announces+Financial+Results+for+the+First+Half+of+2026/26881588.html <p><b>August 6, 2026 Copenhagen, Denmark; </b><br/><b>Interim Report for the Six Months Ended June 30, 2026</b></p> <p><b>Highlights</b></p> <ul type="disc"><li><b>Genmab announced positive Phase 3 results for epcoritamab plus lenalidomide in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL), demonstrating statistically significant improvement in progression-free survival</b></li><li><b>Genmab revenue </b><b>increased</b> <b>25%</b><b> compared to the first six months of </b><b>2025</b><b>, to </b><b>$2,051 million</b></li><li><b>Genmab 2026 financial guidance updated</b><br/><br/></li></ul> <p>“The second quarter of 2026 delivered clinical progress for our late-stage portfolio. Epcoritamab continued to demonstrate its potential as a core therapy across the spectrum of B-cell malignancies, with strong data across multiple treatment settings and http://www.streetinsider.com/Globe+Newswire/Genmab+Announces+Financial+Results+for+the+First+Half+of+2026/26881588.html Thu, 06 Aug 2026 11:01:00 -0400 0MGB GMAB GMAB O.00290225 http://www.streetinsider.com/Globe+Newswire/Genmab+Announces+Financial+Results+for+the+First+Half+of+2026/26881588.html <p><b>August 6, 2026 Copenhagen, Denmark; </b><br/><b>Interim Report for the Six Months Ended June 30, 2026</b></p> <p><b>Highlights</b></p> <ul type="disc"><li><b>Genmab announced positive Phase 3 results for epcoritamab plus lenalidomide in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL), demonstrating statistically significant improvement in progression-free survival</b></li><li><b>Genmab revenue </b><b>increased</b> <b>25%</b><b> compared to the first six months of </b><b>2025</b><b>, to </b><b>$2,051 million</b></li><li><b>Genmab 2026 financial guidance updated</b><br/><br/></li></ul> <p>“The second quarter of 2026 delivered clinical progress for our late-stage portfolio. Epcoritamab continued to demonstrate its potential as a core therapy across the spectrum of B-cell malignancies, with strong data across multiple treatment settings and http://www.streetinsider.com/Globe+Newswire/Genmab+Announces+Financial+Results+for+the+First+Half+of+2026/26881588.html Thu, 06 Aug 2026 11:01:00 -0400 0MGB GMAB GMAB O.00290225 http://www.streetinsider.com/FDA/Genmab+and+AbbVie+say+epcoritamab+trial+missed+U.S.+survival+goal/26807823.html <p>Genmab A/S (Nasdaq: GMAB) and AbbVie (NYSE: ABBV) have clarified that overall survival was the sole U.S. primary endpoint in the Phase 3 EPCORE DLBCL-1 trial evaluating epcoritamab, and that the study did not meet that endpoint.</p> <p>The companies issued the clarification on July 23, 2026, following topline results announced on January 16, 2026, and additional data presented at the European Hematology Association Congress on June 12, 2026.</p> <p>EPCORE DLBCL-1 is a global, open-label, randomized trial that compared monotherapy epcoritamab against investigator's choice of chemoimmunotherapy — either rituximab plus gemcitabine plus oxaliplatin or bendamustine plus rituximab — in adults with relapsed or http://www.streetinsider.com/FDA/Genmab+and+AbbVie+say+epcoritamab+trial+missed+U.S.+survival+goal/26807823.html Thu, 23 Jul 2026 16:00:18 -0400 ABBV GMAB http://www.streetinsider.com/FDA/Genmab+and+AbbVie+say+epcoritamab+trial+missed+U.S.+survival+goal/26807823.html <p>Genmab A/S (Nasdaq: GMAB) and AbbVie (NYSE: ABBV) have clarified that overall survival was the sole U.S. primary endpoint in the Phase 3 EPCORE DLBCL-1 trial evaluating epcoritamab, and that the study did not meet that endpoint.</p> <p>The companies issued the clarification on July 23, 2026, following topline results announced on January 16, 2026, and additional data presented at the European Hematology Association Congress on June 12, 2026.</p> <p>EPCORE DLBCL-1 is a global, open-label, randomized trial that compared monotherapy epcoritamab against investigator's choice of chemoimmunotherapy — either rituximab plus gemcitabine plus oxaliplatin or bendamustine plus rituximab — in adults with relapsed or http://www.streetinsider.com/FDA/Genmab+and+AbbVie+say+epcoritamab+trial+missed+U.S.+survival+goal/26807823.html Thu, 23 Jul 2026 16:00:18 -0400 ABBV GMAB http://www.streetinsider.com/Press+Releases/Genmab+and+AbbVie+Provide+Clarification+on+Phase+3+EPCORE%C2%AE+DLBCL-1+Trial+Evaluating+Epcoritamab+%28DuoBody%C2%AE-CD3xCD20%29+in+Patients+with+RelapsedRefractory+Diffuse+Large+B-cell+Lymphoma+%28DLBCL%29/26807808.html <p><b>Media Release</b></p> <p><b>COPENHAGEN, Denmark and NORTH CHICAGO, Ill.; July 23, 2026</b></p> <ul type="disc"><li><b>Genmab and AbbVie clarify overall survival (OS) was the sole U.S. primary endpoint in the Phase 3 EPCORE</b>^<b>®</b><b> DLBCL-1 trial and was not met</b></li></ul> <p><a href="https://www.globenewswire.com/Tracker?data=u0Jh0AP-7okDUEpzV-qPn-mR0i0GSIm51lflDXyGHeZHle8R1_rkgnlC1hRpnvkBumGsUrsYU5BvaZiU0C6cDg==" rel="nofollow" target="_blank"><b>Genmab A/S</b></a> <b>(Nasdaq: GMAB)</b><b> and </b><b>AbbVie (NYSE: ABBV) </b><b>today</b><b> provided </b><b>clarification </b><b>on </b><b>the primary endpoints from the </b><b>Phase 3 EPCORE</b>^<b>®</b><b> DLBCL-1 study</b> evaluating monotherapy epcoritamab (DuoBody^®-CD3xCD20)<b>,</b> a T-cell engaging bispecific antibody administered subcutaneously, compared with investigator's choice of chemoimmunotherapy (CIT) of either rituximab plus gemcitabine plus oxaliplatin (R-GemOx) or bendamustine plus rituximab (BR) in adults with relapsed or http://www.streetinsider.com/Press+Releases/Genmab+and+AbbVie+Provide+Clarification+on+Phase+3+EPCORE%C2%AE+DLBCL-1+Trial+Evaluating+Epcoritamab+%28DuoBody%C2%AE-CD3xCD20%29+in+Patients+with+RelapsedRefractory+Diffuse+Large+B-cell+Lymphoma+%28DLBCL%29/26807808.html Thu, 23 Jul 2026 16:00:00 -0400 ABBV GMAB http://www.streetinsider.com/Press+Releases/Genmab+and+AbbVie+Provide+Clarification+on+Phase+3+EPCORE%C2%AE+DLBCL-1+Trial+Evaluating+Epcoritamab+%28DuoBody%C2%AE-CD3xCD20%29+in+Patients+with+RelapsedRefractory+Diffuse+Large+B-cell+Lymphoma+%28DLBCL%29/26807808.html <p><b>Media Release</b></p> <p><b>COPENHAGEN, Denmark and NORTH CHICAGO, Ill.; July 23, 2026</b></p> <ul type="disc"><li><b>Genmab and AbbVie clarify overall survival (OS) was the sole U.S. primary endpoint in the Phase 3 EPCORE</b>^<b>®</b><b> DLBCL-1 trial and was not met</b></li></ul> <p><a href="https://www.globenewswire.com/Tracker?data=u0Jh0AP-7okDUEpzV-qPn-mR0i0GSIm51lflDXyGHeZHle8R1_rkgnlC1hRpnvkBumGsUrsYU5BvaZiU0C6cDg==" rel="nofollow" target="_blank"><b>Genmab A/S</b></a> <b>(Nasdaq: GMAB)</b><b> and </b><b>AbbVie (NYSE: ABBV) </b><b>today</b><b> provided </b><b>clarification </b><b>on </b><b>the primary endpoints from the </b><b>Phase 3 EPCORE</b>^<b>®</b><b> DLBCL-1 study</b> evaluating monotherapy epcoritamab (DuoBody^®-CD3xCD20)<b>,</b> a T-cell engaging bispecific antibody administered subcutaneously, compared with investigator's choice of chemoimmunotherapy (CIT) of either rituximab plus gemcitabine plus oxaliplatin (R-GemOx) or bendamustine plus rituximab (BR) in adults with relapsed or http://www.streetinsider.com/Press+Releases/Genmab+and+AbbVie+Provide+Clarification+on+Phase+3+EPCORE%C2%AE+DLBCL-1+Trial+Evaluating+Epcoritamab+%28DuoBody%C2%AE-CD3xCD20%29+in+Patients+with+RelapsedRefractory+Diffuse+Large+B-cell+Lymphoma+%28DLBCL%29/26807808.html Thu, 23 Jul 2026 16:00:00 -0400 ABBV GMAB http://www.streetinsider.com/Globe+Newswire/Genmab+and+AbbVie+Provide+Clarification+on+Phase+3+EPCORE%C2%AE+DLBCL-1+Trial+Evaluating+Epcoritamab+%28DuoBody%C2%AE-CD3xCD20%29+in+Patients+with+RelapsedRefractory+Diffuse+Large+B-cell+Lymphoma+%28DLBCL%29/26807808.html <p><b>Media Release</b></p> <p><b>COPENHAGEN, Denmark and NORTH CHICAGO, Ill.; July 23, 2026</b></p> <ul type="disc"><li><b>Genmab and AbbVie clarify overall survival (OS) was the sole U.S. primary endpoint in the Phase 3 EPCORE</b>^<b>®</b><b> DLBCL-1 trial and was not met</b></li></ul> <p><a href="https://www.globenewswire.com/Tracker?data=u0Jh0AP-7okDUEpzV-qPn-mR0i0GSIm51lflDXyGHeZHle8R1_rkgnlC1hRpnvkBumGsUrsYU5BvaZiU0C6cDg==" rel="nofollow" target="_blank"><b>Genmab A/S</b></a> <b>(Nasdaq: GMAB)</b><b> and </b><b>AbbVie (NYSE: ABBV) </b><b>today</b><b> provided </b><b>clarification </b><b>on </b><b>the primary endpoints from the </b><b>Phase 3 EPCORE</b>^<b>®</b><b> DLBCL-1 study</b> evaluating monotherapy epcoritamab (DuoBody^®-CD3xCD20)<b>,</b> a T-cell engaging bispecific antibody administered subcutaneously, compared with investigator's choice of chemoimmunotherapy (CIT) of either rituximab plus gemcitabine plus oxaliplatin (R-GemOx) or bendamustine plus rituximab (BR) in adults with relapsed or http://www.streetinsider.com/Globe+Newswire/Genmab+and+AbbVie+Provide+Clarification+on+Phase+3+EPCORE%C2%AE+DLBCL-1+Trial+Evaluating+Epcoritamab+%28DuoBody%C2%AE-CD3xCD20%29+in+Patients+with+RelapsedRefractory+Diffuse+Large+B-cell+Lymphoma+%28DLBCL%29/26807808.html Thu, 23 Jul 2026 16:00:00 -0400 ABBV GMAB http://www.streetinsider.com/Globe+Newswire/Genmab+and+AbbVie+Provide+Clarification+on+Phase+3+EPCORE%C2%AE+DLBCL-1+Trial+Evaluating+Epcoritamab+%28DuoBody%C2%AE-CD3xCD20%29+in+Patients+with+RelapsedRefractory+Diffuse+Large+B-cell+Lymphoma+%28DLBCL%29/26807808.html <p><b>Media Release</b></p> <p><b>COPENHAGEN, Denmark and NORTH CHICAGO, Ill.; July 23, 2026</b></p> <ul type="disc"><li><b>Genmab and AbbVie clarify overall survival (OS) was the sole U.S. primary endpoint in the Phase 3 EPCORE</b>^<b>®</b><b> DLBCL-1 trial and was not met</b></li></ul> <p><a href="https://www.globenewswire.com/Tracker?data=u0Jh0AP-7okDUEpzV-qPn-mR0i0GSIm51lflDXyGHeZHle8R1_rkgnlC1hRpnvkBumGsUrsYU5BvaZiU0C6cDg==" rel="nofollow" target="_blank"><b>Genmab A/S</b></a> <b>(Nasdaq: GMAB)</b><b> and </b><b>AbbVie (NYSE: ABBV) </b><b>today</b><b> provided </b><b>clarification </b><b>on </b><b>the primary endpoints from the </b><b>Phase 3 EPCORE</b>^<b>®</b><b> DLBCL-1 study</b> evaluating monotherapy epcoritamab (DuoBody^®-CD3xCD20)<b>,</b> a T-cell engaging bispecific antibody administered subcutaneously, compared with investigator's choice of chemoimmunotherapy (CIT) of either rituximab plus gemcitabine plus oxaliplatin (R-GemOx) or bendamustine plus rituximab (BR) in adults with relapsed or http://www.streetinsider.com/Globe+Newswire/Genmab+and+AbbVie+Provide+Clarification+on+Phase+3+EPCORE%C2%AE+DLBCL-1+Trial+Evaluating+Epcoritamab+%28DuoBody%C2%AE-CD3xCD20%29+in+Patients+with+RelapsedRefractory+Diffuse+Large+B-cell+Lymphoma+%28DLBCL%29/26807808.html Thu, 23 Jul 2026 16:00:00 -0400 ABBV GMAB http://www.streetinsider.com/Analyst+PT+Change/TD+Cowen+Upgrades+Genmab+AS+%28GMAB%29+to+Buy/26797708.html (Updated - July 22, 2026 6:16 AM EDT) <p>TD Cowen analyst Yaron Werber upgraded Genmab A/S (NASDAQ: GMAB) from Hold to Buy with a price target of $43.00 (from $32.00).</p><p>The analyst commented: "We have conviction Epkinly, Rina-S & peto will offset the $3.6B Darzalex patent cliff. Our stat analysis suggests Epkinly's Ph3 in 1L DLBCL should succeed and look better than POLARIX. Rina-S is ahead in development in POC. Peto could differentiate w/efficacy in HPV+ HNSCC. Stock appears cheap, trading near royalty NPV and H2:26 is catalyst-rich. Raising ests & upgrading to Buy. New PT $43 (+$11)."</p><p>For an analyst ratings summary http://www.streetinsider.com/Analyst+PT+Change/TD+Cowen+Upgrades+Genmab+AS+%28GMAB%29+to+Buy/26797708.html Wed, 22 Jul 2026 06:16:02 -0400 GMAB http://www.streetinsider.com/Upgrades/TD+Cowen+Upgrades+Genmab+AS+%28GMAB%29+to+Buy/26797708.html (Updated - July 22, 2026 6:16 AM EDT) <p>TD Cowen analyst Yaron Werber upgraded Genmab A/S (NASDAQ: GMAB) from Hold to Buy with a price target of $43.00 (from $32.00).</p><p>The analyst commented: "We have conviction Epkinly, Rina-S & peto will offset the $3.6B Darzalex patent cliff. Our stat analysis suggests Epkinly's Ph3 in 1L DLBCL should succeed and look better than POLARIX. Rina-S is ahead in development in POC. Peto could differentiate w/efficacy in HPV+ HNSCC. Stock appears cheap, trading near royalty NPV and H2:26 is catalyst-rich. Raising ests & upgrading to Buy. New PT $43 (+$11)."</p><p>For an analyst ratings summary http://www.streetinsider.com/Upgrades/TD+Cowen+Upgrades+Genmab+AS+%28GMAB%29+to+Buy/26797708.html Wed, 22 Jul 2026 06:16:02 -0400 GMAB